In this respect, the anticancer potential of targeting this PERK–Nrf2 signaling axis has been corroborated by a number of previous studies, both by us [32] and others [56], and suggests that, by combining CDDO-me, an oxidative stress and Nrf2 inducer [25,26], and nelfinavir, a potent ER-stress inducer [27,28], aggressive PCa cells can be sensitized to FUS therapy (Figure 7). The gene discussed is EIF2AK3; the disease is posterior cortical atrophy.